The role of monoamines in the changes in body temperature induced by 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its derivatives

British Journal of Pharmacology

Volumn 160, Issue 5, 2010, Pages 1029-1044

  Docherty, J R ^a   Green, A R ^b  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

3,4 methylenedioxyamphetamine; 3,4 methylenedioxyethamphetamine; 3,4 methylenedioxymethamphetamine; 5 hydroxytrypamine; Dopamine; Hyperthermia; Hypothermia; Noradrenaline; Thermoregulation

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 3,4 METHYLENEDIOXYAMPHETAMINE; 3,4 METHYLENEDIOXYETHAMPHETAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2A ADRENERGIC RECEPTOR; AMPHETAMINE DERIVATIVE; BETA 3 ADRENERGIC RECEPTOR; CLONIDINE; CLOZAPINE; CYTOCHROME P450 2D6; DOPAMINE; FENCLONINE; FLUOXETINE; METHYSERGIDE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NORADRENALIN; REMOXIPRIDE; RISPERIDONE; SEROTONIN; SEROTONIN RECEPTOR; UNCLASSIFIED DRUG; BIOGENIC AMINE;

ADRENERGIC ACTIVITY; ANIMAL HOUSING; BETA ADRENERGIC RECEPTOR BLOCKING; BLOOD FLOW; BODY TEMPERATURE; BRADYCARDIA; BROWN ADIPOSE TISSUE; BRUXISM; DOPAMINE RELEASE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG HALF LIFE; DRUG METABOLISM; ENVIRONMENTAL TEMPERATURE; EXPERIMENTAL GUINEA PIG; HEART FUNCTION; HEAT LOSS; HUMAN; HYPERTHERMIA; HYPOTHERMIA; INDUCED HYPOTHERMIA; LIGAND BINDING; LOCOMOTION; LOW DRUG DOSE; MONKEY; MONOAMINE RELEASE; MONOAMINERGIC SYSTEM; NEUROTOXICITY; NONHUMAN; NORADRENERGIC SYSTEM; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT STRAIN; RECEPTOR AFFINITY; REPEATED DRUG DOSE; REVIEW; ROOM TEMPERATURE; SEROTONIN RELEASE; SINGLE DRUG DOSE; TACHYCARDIA; THERMOGENESIS; THERMOREGULATION; VASOCONSTRICTION; ANALOGS AND DERIVATIVES; ANIMAL; CHEMICALLY INDUCED; DRUG EFFECTS; FEVER; MOTOR ACTIVITY; PATHOPHYSIOLOGY; PHYSIOLOGY; SPECIES DIFFERENCE;

ANIMALS; BIOGENIC MONOAMINES; BODY TEMPERATURE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEVER; HUMANS; HYPOTHERMIA; MOTOR ACTIVITY; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; SPECIES SPECIFICITY;

EID: 77953179368     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00722.x     Document Type: Review

References (173)

1. Al-Dabbagh SG, Idle JR, Smith RL (1981). Animal modelling of human polymorphic drug oxidation - the metabolism of debrisoquine and phenacitin in inbred rat strains. J Pharm Pharmacol 33 : 161 164.
2. Alex KD, Pehek EA (2007). Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol Ther 113 : 296 320.
3. Alexander SP, Mathie A, Peters JA (2008). Guide to Receptors and Channels (GRAC), 3rd edition. Br J Pharmacol 153 (Suppl 2 S1 S209.
4. Al-Sahli W, Ahmad H, Kheradmand F, Connolly C, Docherty JR (2001). Effects of methylenedioxymethamphetamine on noradrenaline-evoked contractions of rat right ventricle and small mesenteric artery. Eur J Pharmacol 422 : 169 174.
5. Arrue A, Gómez FM, Giralt MT (2004). Effects of 3,4-methylenedioxymethamphetamine ('ecstasy') on the jaw-opening reflex and on the α-adrenoceptors which regulate this reflex in the anesthetized rat. Eur J Oral Sci 112 : 127 133.
6. Aulakh CS, Mazzola-Pomietto P, Murphy DL (1995). Long-term antidepressant treatments alter 5-HT2A and 5-HT2C receptor-mediated hyperthermia in fawn-hooded rats. Eur J Pharmacol 282 : 65 70.
7. Badon LA, Hicks A, Lord K, Ogden BA, Meleg-Smith S, Varner KJ (2002). Changes in cardiovascular responsiveness and cardiotoxicity elicited during binge administration of ecstasy. J Pharmacol Exp Ther 302 : 898 907.
8. Banks ML, Sprague JE, Kisor DF, Czoty PW, Nichols DE, Nader MA (2007). Ambient temperature effects on 3,4-methylenedioxymethamphetamine-induced thermodysregulation and pharmacokinetics in male monkeys. Drug Metab Dispos 35 : 1840 1845.
9. Bankson MG, Cunningham KA (2002). Pharmacological studies of the acute effects of (+)-3,4-methylenedioxymethamphetamine on locomotor activity: role of 5-HT(1B/1D) and 5-HT(2) receptors. Neuropsychopharmacology 26 : 40 52.
10. Battaglia G, Brooks BP, Kulsakdinun C, De Souza EB (1988). Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. Eur J Pharmacol 149 : 159 163.
11. Baumann MH, Zolkowska D, Kim I, Scheidweiler KB, Rothman RB, Huestis MA (2009). Effects of dose and route of administration on pharmacokinetics of (+ or -)-3,4-methylenedioxymethamphetamine in the rat. Drug Metab Dispos 37 : 2163 2170.
12. Berger UV, Gu XF, Azmitia EC (1992). The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, p-chloramphetamine and fenfluramine induce 5-hydroxytryptamine release via a common mechanism blocked by fluoxetine and cocaine. Eur J Pharmacol 215 : 153 160.
13. Beveridge TJ, Mechan AO, Sprakes M, Pei Q, Zetterstrom TS, Green AR et al 2004). Effect of 5-HT depletion by MDMA on hyperthermia and Arc mRNA induction in rat brain. Psychopharmacology 173 : 346 352.
14. Bexis S, Docherty JR (2005). Role of α2A-adrenoceptors in the effects of MDMA on body temperature in the mouse. Br J Pharmacol 146 : 1 6.
15. Bexis S, Docherty JR (2006). Effects of MDMA, MDA and MDEA on blood pressure, heart rate, locomotor activity and body temperature in the rat involve α-adrenoceptors. Br J Pharmacol 147 : 926 934.
16. Bexis S, Docherty JR (2008). Role of α(1)-adrenoceptor subtypes in the effects of methylenedioxy methamphetamine (MDMA) on body temperature in the mouse. Br J Pharmacol 153 : 591 597.
17. Bexis S, Docherty JR (2009). Role of α1- and β3-adrenoceptors in the modulation by SR59230A of the effects of MDMA on body temperature in the mouse. Br J Pharmacol 158 : 259 266.
18. Bill DJ, Knight M, Forster EA, Fletcher A (1991). Direct evidence for an important species difference in the mechanism of 8-OH-DPAT-induced hypothermia. Br J Pharmacol 103 : 1857 1864.
19. Blessing WW, Seaman B, Pedersen NP, Ootsuka Y (2003). Clozapine reverses hyperthermia and sympathetically mediated cutaneous vasoconstriction induced by 3,4-methylenedioxymethamphetamine (ecstasy) in rabbits and rats. J Neurosci 23 : 6385 6391.
20. Blessing WW, Zilm A, Ootsuka Y (2006). Clozapine reverses increased brown adipose tissue thermogenesis induced by 3,4-methylenedioxymethamphetamine and by cold exposure in conscious rats. Neuroscience 141 : 2067 2073.
21. Bligh J (1979). The central neurology of mammalian thermoregulation. Neuroscience 4 : 1213 1236.
22. Brahmadevara N, Shaw AM, MacDonald A (2004). α1-Adrenoceptor antagonist properties of CGP 12177A and other beta-adrenoceptor ligands: evidence against beta(3)- or atypical beta-adrenoceptors in rat aorta. Br J Pharmacol 142 : 781 787.
23. Brede M, Nagy G, Philipp M, Sorensen JB, Lohse MJ, Hein L (2003). Differential control of adrenal and sympathetic catecholamine release by α2-adrenoceptor subtypes. Mol Endocrinol 17 : 1640 1646.
24. Broadley KJ (2010). The vascular effects of trace amines and amphetamines. Pharmacol Ther 125 : 363 375.
25. Broening HW, Bowyer JF, Slikker W Jr. (1995). Age-dependent sensitivity of rats to the long-term effects of the serotonergic neurotoxicant (+/-)-3,4-methylenedioxymethamphetamine (MDMA) correlates with the magnitude of the MDMA-induced thermal response. J Pharmacol Exp Ther 275 : 325 333.
26. Brown C, Osterloh J (1987). Multiple severe complications from recreational ingestion of MDMA ('ecstasy'). J Am Med Assoc 258 : 780 781.
27. Bylund DB, Eikenberg DC, Hieble JP, Langer SZ, Lefkowitz RJ, Minneman KP et al 1994). International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol Revs 46 : 121 136.
28. Carvalho M, Carvalho F, Remião F, de Lourdes Pereira M, Pires-das-Neves R, de Lourdes Bastos M (2002). Effect of 3,4- methylenedioxymethamphetamine ('ecstasy') on body temperature and liver antioxidant status in mice: influence of ambient temperature. Arch Toxicol 76 : 166 172.
29. Chance MRA (1946). Aggregation as a factor influencing the toxicity of sympathomimetic amines in mice. J Pharmacol Exp Ther 87 : 214 219.
30. Chotani MA, Flavahan S, Mitra S, Daunt D, Flavahan NA (2000). Silent α(2C)-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries. Am J Physiol Heart Circ Physiol 278 : H1075 H1083.
31. Cleary L, Docherty JR (2003). Actions of amphetamine derivatives and cathinone at the noradrenaline transporter. Eur J Pharmacol 476 : 31 34.
32. Cleary L, Buber R, Docherty JR (2002a). Effects of amphetamine derivatives and cathinone on noradrenaline-evoked contractions of rat right ventricle. Eur J Pharmacol 451 : 303 308.
33. Cleary L, Vandeputte C, Docherty JR (2002b). Investigation of neurotransmission in vas deferens from α(2A/D)-adrenoceptor knockout mice. Br J Pharmacol 136 : 857 864.
34. Colado MI, Williams JL, Green AR (1995). The hyperthermic and neurotoxic effects of 'ecstasy' (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the dark agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype. Br J Pharmacol 115 : 1281 1289.
35. Colado MI, Camarero J, Mechan AO, Sanchez V, Esteban B, Elliott JM et al 2001). A study of the mechanisms involved in the neurotoxic action of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') on dopamine neurones in mouse brain. Br J Pharmacol 134 : 1711 1723.
36. Cole JC, Sumnall HR (2003a). Altered states: the clinical effects of 'ecstasy'. Pharmacol Ther 98 : 35 58.
37. Cole JC, Sumnall HR (2003b). The preclinical behavioural pharmacology of 3,4-methylenedioxymethamphetamine (MDMA). Neurosci Biobehav Revs 27 : 199 217.
38. Crean RD, Davis SA, Von Huben SN, Lay CC, Katner SN, Taffe MA (2006). Effects of (+/-)3,4-methylenedioxymethamphetamine, (+/-)3,4- methylenedioxyamphetamine and methamphetamine on temperature and activity in rhesus macaques. Neuroscience 142 : 515 525.
39. Crean RD, Davis SA, Taffe MA (2007). Oral administration of (+/-)3,4-methylenedioxymethamphetamine and (+)methamphetamine alters temperature and activity in rhesus macaques. Pharmacol Biochem Behav 87 : 11 19.
40. Crespi D, Mennini T, Gobbi M (1997). Carrier-dependent and Ca(2+)-dependent 5-HT and dopamine release induced by (+)-amphetamine, 3,4-methylendioxymethamphetamine, p-chloroamphetamine and (+)-fenfluramine. Br J Pharmacol 121 : 1735 1743.
41. Cronin MJ (1976). p-Chlorophenylalanine hyperthermia in a warm environment: reversal with 5-hydroxytryptophan. Brain Res 112 : 194 199.
42. Dafters RI (1994). Effect of ambient temperature on hyperthermia and hyperkinesis induced by 3,4-methylenedioxymethamphetamine (MDMA or 'ecstasy') in rats. Psychopharmacology 114 : 505 508.
43. Dafters RI (1995). Hyperthermia following MDMA administration in rats: effects of ambient temperature, water consumption, and chronic dosing. Physiol Behav 58 : 877 882.
44. Dafters RI, Lynch E (1998). Persistent loss of thermoregulation in the rat induced by 3,4-methylenedioxymethamphetamine (MDMA or 'ecstasy') but not by fenfluramine. Psychopharmacology 138 : 207 212.
45. Daws LC, Irvine RJ, Callaghan PD, Toop NP, White JM, Bochner F (2000). Differential behavioural and neurochemical effects of para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine in the rat. Prog Neuropsychopharmacol Biol Psychiatry 24 : 955 977.
46. Di Matteo V, Di Giovanni G, Pierucci M, Esposito E (2008). Serotonin control of central dopaminergic function: focus on in vivo microdialysis studies. Prog Brain Res 172 : 7 44.
47. Docherty JR (1998). Subtypes of functional α1- and α2-adrenoceptors. Eur J Pharmacol 361 : 1 15.
48. Dowling GP, McDonough ET, Bost RO (1987). 'Eve' and 'ecstasy'. A report of five deaths associated with the use of MDEA and MDMA. J Am Med Assoc 257 : 1615 1617.
49. Duka I, Gavras I, Johns C, Handy DE, Gavras H (2000). Role of the postsynaptic α(2)-adrenergic receptor subtypes in catecholamine-induced vasoconstriction. Gen Pharmacol 34 : 101 106.
50. Ensslin HK, Maurer HH, Gouzoulis E, Hermle L, Kovar KA (1996). Metabolism of racemic 3,4-methylenedioxyethylamphetamine in humans. Isolation, identification, quantification, and synthesis of urinary metabolites. Drug Metab Dispos 24 : 813 820.
51. Fantegrossi WE, Godlewski T, Karabenick RL, Stephens JM, Ullrich T, Rice KC et al 2003). Pharmacological characterization of the effects of 3,4-methylenedioxymethamphetamine ('ecstasy') and its enantiomers on lethality, core temperature, and locomotor activity in singly housed and crowded mice. Psychopharmacology 166 : 202 211.
52. Farré M, Abanades S, Roset PN, Peiro AM, Torrens M, O'Mathuna B et al 2007). Pharmacological interaction between 3,4 and methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokinetics. J Pharmacol Exp Ther 323 : 954 962.
53. Farver DK (2003). Neuroleptic malignant syndrome induced by atypical antipsychotics. Expert Opin Drug Saf 2 : 21 35.
54. Fischer JF, Cho AK (1979). Chemical release of dopamine from striatal homogenates: evidence for an exchange diffusion model. J Pharmacol Exp Ther 208 : 203 209.
55. Fitzgerald JL, Reid JJ (1993). Interactions of methylenedioxymethamphetamine with monoamine transmitter release mechanisms in rat brain slices. Naunyn Schmiedebergs Arch Pharmacol 347 : 313 323.
56. Fitzgerald JL, Reid JJ (1994). Sympathomimetic actions of methylenedioxymethamphetamine in rat and rabbit isolated cardiovascular tissues. J Pharm Pharmacol 46 : 826 832.
57. Freedman RR, Johanson CE, Tancer ME (2005). Thermoregulatory effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology 183 : 248 256.
58. Fuller MA, Borovicka MC, Jaskiw GE, Simon MR, Kwon K, Konicki PE (1996). Clozapine-induced urinary incontinence: incidence and treatment with ephedrine. J Clin Psychiatry 57 : 514 518.
59. Gabrielsson J, Green AR (2009). Quantitative pharmacology or pharmacokinetic pharmacodynamic integration should be a vital component in integrative pharmacology. J Pharmacol Exp Ther 331 : 1 8.
60. Gavin KT, Colgan MP, Moore D, Shanik G, Docherty JR (1997). α2C-adrenoceptors mediate contractile responses to noradrenaline in the human saphenous vein. Naunyn Schmiedebergs Arch Pharmacol 355 : 406 411.
61. Giacchino JL, Schtel ER, Horowitz JM, Horowitz BA (1983). Effect of p-chlorophenylalanine on thermoregulation in unrestrained rats. Am J Physiol 244 : R299 R302.
62. Ginsberg MD, Hertzman M, Schmidt-Nowara WW (1970). Amphetamine intoxication with coagulopathy, hyperthermia and reversible renal failure. A syndrome resmbling heatstroke. Ann Intern Med 73 : 81 85.
63. Goni-Allo B, Mathúna BÓ, Segura M, Puerta E, Lasheras B, de la Torre R, Aguirre N (2008). The relationship between core body temperature and 3,4-methylenedioxymethamphetamine metabolism in rats: implications for neurotoxicity. Psychopharmacology 197 : 263 278.
64. Goodwin GM, Green AR (1985). A behavioural and biochemical study in mice and rats of putative selective agonists and antagonists for 5-HT1 and 5-HT2 receptors. Br J Pharmacol 84 : 743 753.
65. Goodwin GM, De Souza RJ, Green AR (1985). The pharmacology of the hypothermic response in mice to 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT). A model of presynaptic 5-HT1 function. Neuropharmacology 24 : 1187 1194.
66. Gordon CJ, Fogelson L (1994). Metabolic and thermoregulatory responses of the rat maintained in acrylic or wire screen cages: implications for pharmacological studies. Physiol Behav 56 : 73 79.
67. Gordon CJ, Watkinson WP, O'Callaghan JP, Miller DB (1991). Effects of 3,4-methylenedioxymethamphetamine on autonomic thermoregulatory responses of the rat. Pharmacol Biochem Behav 38 : 339 344.
68. Gouzoulis E, von Bardeleben U, Rupp A, Kovar KA, Hermle L (1993). Neuroendocrine and cardiovascular effects of MDE in healthy volunteers. Neuropsychopharmacology 8 : 187 193.
69. Gouzoulis-Mayfrank E, Daumann J (2009). Neurotoxicity of drugs of abuse - the case of methylenedioxyamphetamines (MDMA, ecstasy), and amphetamines. Dialogues Clin Neurosci 11 : 305 317.
70. Grahame-Smith DG (1971). Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivivty in rats treated with a monoamine oxidase inhibitor and L-tryptophan. J Neurochem 18 : 1053 1066.
71. Grant RT (1963). Vasodilatation and body warming in the rat. J Physiol 167 : 311 317.
72. Green AR (2004). MDMA fact and fallacy, and the need to increase knowledge in both the scientific and popular press. Psychopharmacology 173 : 231 233.
73. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI (2003). The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'). Pharmacol Rev 55 : 463 508.
74. Green AR, Sanchez V, O'Shea E, Saadat KS, Elliott JM, Colado MI (2004). Effect of ambient temperature and a prior neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA) on the hyperthermic response of rats to a single or repeated ('binge' ingestion) low dose of MDMA. Psychopharmacology 173 : 264 269.
75. Green AR, O'Shea E, Saadat KS, Elliott JM, Colado MI (2005). Studies on the effect of MDMA ('ecstasy') on the body temperature of rats housed at different ambient room temperatures. Br J Pharmacol 146 : 306 312.
76. Green AR, Gabrielsson J, Marsden CA, Fone KCF (2009). MDMA: on the translation from rodent to human dosing. Psychopharmacology 204 : 375 378.
77. Gudelsky GA, Yamamoto BK (2008). Actions of 3,4- methylenedioxymethamphetamine (MDMA) on cerebral dopaminergic, serotonergic and cholinergic neurons. Pharmacol Biochem Behav 90 : 198 207.
78. Gudelsky GA, Koenig JI, Meltzer HY (1986). Thermoregulatory responses to serotonin (5-HT) receptor stimulation in the rat. Evidence for opposing roles of 5-HT2 and 5-HT1A receptors. Neuropharmacology 25 : 1307 1313.
79. Gunn JA, Gurd MR (1940). The action of some amines related to adrenaline. Cyclohexylalkylamines. J Physiol 97 : 453 470.
80. Hammersley R, Ditton J, Smith I, Short E (1999). Patterns of ecstasy use by drug users. Br J Criminol 39 : 625 647.
81. Hayner GN, McKinney H (1986). MDMA. The dark side of ecstasy. J Psychoactive Drugs 18 : 341 347.
82. Hegadoren KM, Baker GB, Bourin M (1999). 3,4-Methylenedioxy analogues of amphetamine: defining the risks to humans. Neurosci Biobehav Rev 23 : 539 553.
83. Hein L, Altman JD, Kobilka BK (1999). Two functionally distinct α2-adrenergic receptors regulate sympathetic neurotransmission. Nature 402 : 181 184.
84. Herin DV, Liu S, Ullrich T, Rice KC, Cunningham KA (2005). Role of the serotonin 5-HT2A receptor in the hyperlocomotive and hyperthermic effects of (+)-3,4-methylenedioxymethamphetamine. Psychopharmacology 178 : 505 513.
85. Hjorth S (1985). Hypothermia in the rat induced by the potent serotoninergic agent 8-OH-DPAT. J Neural Transm 61 : 131 135.
86. Hjorth S, Carlsson A (1987). Postsynaptic dopamine (DA) receptor stimulator properties of the putative DA autoreceptor-selective agonist BHT-920 uncovered by co-treatment with the D-1 agonist SK & F38393. Psychopharmacology 173 : 534 537.
87. Ho SL, Honner V, Docherty JR (1998). Investigation of the subtypes of α2-adrenoceptor mediating prejunctional inhibition in rat atrium and cerebral cortex. Naunyn Schmiedebergs Arch Pharmacol 357 : 634 639.
88. Hunter JC, Fontana DJ, Hedley LR, Jasper JR, Lewis R, Link RE et al 1997). Assessment of the role of α2-adrenoceptor subtypes in the antinociceptive, sedative and hypothermic action of dexmedetomidine in transgenic mice. Br J Pharmacol 122 : 1339 1344.
89. Irvine RJ, Keane M, Felgate P, McCann UD, Callaghan PD, White JM (2006). Plasma drug concentrations and physiological measures in 'dance party' participants. Neuropsychopharmacology 31 : 424 430.
90. Jaehne EJ, Salem A, Irvine RJ (2007). Pharmacological and behavioral determinants of cocaine, methamphetamine, 3,4-methylenedioxymethamphetamine, and para-methoxyamphetamine-induced hyperthermia. Psychopharmacology 194 : 41 52.
91. Jaehne EJ, Salem A, Irvine RJ (2008). The effect of long-term repeated exposure to 3,4-methylenedioxymethamphetamine on cardiovascular and thermoregulatory changes. Psychopharmacology 201 : 161 170.
92. Johnson MP, Conarty PF, Nichols DE (1991). 3Hmonoamine releasing and uptake inhibition properties of 3,4-methylenedioxymethamphetamine and p-chloroamphetamine analogues. Eur J Pharmacol 200 : 9 16.
93. Johnson EA, Sharp DS, Miller DB (2000). Restraint as a stressor in mice: against the dopaminergic neurotoxicity of d-MDMA, low body weight mitigates restraint-induced hypothermia and consequent neuroprotection. Brain Res 875 : 107 118.
94. Johnson EA, O'Callaghan JP, Miller DB (2002a). Chronic treatment with supraphysiological levels of corticosterone enhances d-MDMA-induced dopaminergic neurotoxicity in the C57BL/6J female mouse. Brain Res 933 : 130 138.
95. Johnson EA, Shvedova AA, Kisin E, O'Callaghan JP, Kommineni C, Miller DB (2002b). d-MDMA during vitamin E deficiency: effects on dopaminergic neurotoxicity and hepatotoxicity. Brain Res 933 : 150 163.
96. Kalant H (2001). The pharmacology and toxicology of 'ecstasy' (MDMA) and related drugs. Can Med Assoc J 165 : 917 928.
97. Kendrick WC, Hull AR, Knochel JP (1977). Rhabdomolysis and shock after intravenous amphetamine administration. Ann Intern Med 86 : 381 387.
98. Lähdesmäki J, Sallinen J, MacDonald E, Sirviö J, Scheinin M (2003). α2-Adrenergic drug effects on brain monoamines, locomotion, and body temperature are largely abolished in mice lacking the α2A- adrenoceptor subtype. Neuropharmacology 44 : 882 892.
99. Lavelle A, Honner V, Docherty JR (1999). Investigation of the prejunctional α2-adrenoceptor mediated actions of MDMA in rat atrium and vas deferens. Br J Pharmacol 128 : 975 980.
100. Leblais V, Pourageaud F, Ivorra MD, Guibert C, Marthan R, Muller B (2004). Role of α-adrenergic receptors in the effect of the beta-adrenergic receptor ligands, CGP 12177, bupranolol, and SR 59230A, on the contraction of rat intrapulmonary artery. J Pharmacol Exp Ther 309 : 137 145.
101. Leggio GM, Cathala A, Neny M, Rouge-Pont F, Drago F, Piazza PV et al 2009). In vivo evidence that constitutive activity of serotonin2C receptors in the medial prefrontal cortex participates in the control of dopamine release in the rat nucleus accumbens: differential effects of inverse agonist versus antagonist. J Neurochem 111 : 614 623.
102. Leonardi ET, Azmitia EC (1994). MDMA (ecstasy) inhibition of MAO type A and type B: comparisons with fenfluramine and fluoxetine (Prozac). Neuropsychopharmacology 10 : 231 238.
103. Liechti ME, Vollenweider FX (2000a). The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine ('ecstasy') in healthy volunteers. J Psychopharmacol 14 : 269 274.
104. Liechti ME, Vollenweider FX (2000b). Acute psychological and physiological effects of MDMA (ecstasy) after haloperidol treatment in healthy humans. Eur Neuropsychopharmacol 10 : 289 295.
105. Liechti ME, Saur MR, Gamma A, Hell D, Vollenweider FX (2000). Psychological and physiological effects of MDMA ('ecstasy') after pretreatment with the 5-HT(2) antagonist ketanserin in healthy humans. Neuropsychopharmacology 23 : 396 404.
106. McCann UD, Slate SO, Ricaurte GA (1996). Adverse reactions with 3,4-methylenedioxymethamphetamine (MDMA; 'ecstasy'. Drug Safety 15 : 107 115.
107. McDaid J, Docherty JR (2001). Vascular actions of MDMA involve α1 and α2-adrenoceptors in the anaesthetized rat. Br J Pharmacol 133 : 429 437.
108. Malberg JE, Seiden LS (1998). Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat. J Neurosci 18 : 5086 5094.
109. Malberg JE, Sabol KE, Seiden LS (1996). Co-administration of MDMA with drugs that protect against MDMA neurotoxicity produces different effects on body temperature in the rat. J Pharmacol Exp Ther 278 : 258 267.
110. Malpass A, White JM, Irvine RJ, Somogyi AA, Bochner F (1999). Acute toxicity of 3,4-methylenedioxymethamphetamine (MDMA) in Sprague-Dawley and dark agouti rats. Pharmacol Biochem Behav 64 : 29 34.
111. Manara L, Badone D, Baroni M, Boccardi G, Cecchi R, Croci T et al 1996). Functional identification of rat atypical beta-adrenoceptors by the first beta 3-selective antagonists, aryloxypropanolaminotetralins. Br J Pharmacol 117 : 435 442.
112. Matsunaga E, Zanger UM, Hardwick JP, Gelboin HV, Meyer UA, Gonzalez FJ (1989). The CYP2D gene subfamily: analysis of the molecular basis of the debrisoquine4-hydroxylase deficiency in DA rats. Biochem 28 : 7349 7355.
113. Mazzola-Pomietto P, Aulakh CS, Tolliver T, Murphy DL (1997). Functional subsensitivity of 5-HT2A and 5-HT2C receptors mediating hyperthermia following acute and chronic treatment with 5-HT2A/2C receptor antagonists. Psychopharmacology 130 : 144 151.
114. Mechan AO, O'Shea E, Elliott JM, Colado MI, Green AR (2001). A neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) to rats results in a long-term defect in thermoregulation. Psychopharmacology 155 : 413 418.
115. Mechan AO, Esteban B, O'shea E, Elliott JM, Colado MI, Green AR (2002). The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') to rats. Br J Pharmacol 135 : 170 180.
116. Miller DB, O'Callaghan JP (1994). Environment-, drug- and stress-induced alterations in body temperature affect the neurotoxicity of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther 270 : 752 760.
117. Mills EM, Rusyniak DE, Sprague JE (2004). The role of the sympathetic nervous system and uncoupling proteins in the thermogenesis induced by 3,4-methylenedioxymethamphetamine. J Mol Med 82 : 787 799.
118. Mittleman MA, Mintzer D, Maclure M, Tofler GH, Sherwood JB, Muller JE (1999). Triggering of myocardial infarction by cocaine. Circulation 99 : 2737 2741.
119. Morimoto T, Hashimoto K, Yasumatsu H, Tanaka H, Fujimura M, Kuriyama M et al 2002). Neuropharmacological profile of a novel potential atypical antipsychotic drug Y-931 (8-fluoro-12-(4-methylpiperazin-1-yl)- 6H-1benzothieno2,3-b1,5 benzodiazepine maleate). Neuropsychopharmacology 26 : 456 467.
120. Myers RD, Beleslin DB, Rezvani AH (1987). Hypothermia: role of α1- and α2-noradrenergic receptors in the hypothalamus of the cat. Pharmacol Biochem Behav 26 : 373 379.
121. Nasrallah HA (2008). Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 13 : 27 35.
122. Nichols DE, Lloyd DH, Hoffman AJ, Nichols MB, Yim GK (1982). Effects of certain hallucinogenic amphetamine analogues on the release of 3Hserotonin from rat brain synaptosomes. J Med Chem 25 : 530 535.
123. Nisoli E, Tonello C, Landi M, Carruba MO (1996). Functional studies of the first selective beta 3-adrenergic receptor antagonist SR 59230A in rat brown adipocytes. Mol Pharmacol 49 : 7 14.
124. O'Cain PA, Hletko SB, Ogden BA, Varner KJ (2000). Cardiovascular and sympathetic responses and reflex changes elicited by MDMA. Physiol Behav 70 : 141 148.
125. O'Loinsigh ED, Boland G, Kelly JP, O'Boyle KM (2001). Behavioural, hyperthermic and neurotoxic effects of 3,4-methylenedioxymethamphetamine analogues in the Wistar rat. Prog Neuropsychopharmacol Biol Psychiatry 25 : 621 638.
126. Ootsuka Y, Blessing WW (2006). Thermogenesis in brown adipose tissue: increase by 5-HT2A receptor activation and decrease by 5-HT1A receptor activation in conscious rats. Neurosci Letts 395 : 170 174.
127. O'Shea E, Esteban B, Camarero J, Green AR, Colado MI (2001). Effect of GBR 12909 and fluoxetine on the acute and long term changes induced by MDMA ('ecstasy') on the 5-HT and dopamine concentrations in mouse brain. Neuropharmacology 40 : 65 74.
128. O'Shea E, Orio L, Escobedo I, Sanchez V, Camarero J, Green AR et al 2006). MDMA-induced neurotoxicity: long-term effects on 5-HT biosynthesis and the influence of ambient temperature. Br J Pharmacol 148 : 778 785.
129. Parrott AC (2005). Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or ecstasy. J Psychopharmacol 19 : 71 83.
130. Pedersen NP, Blessing WW (2001). Cutaneous vasoconstriction contributes to hyperthermia induced by 3,4-methylenedioxymethamphetamine (ecstasy) in conscious rabbits. J Neurosci 21 : 8648 8654.
131. Pettinger WA, Keeton TK, Campbell WB, Harper DC (1976). Evidence for a renal alpha-adrenergic receptor inhibiting renin release. Circ Res 38 : 338 346.
132. Philipp M, Brede M, Hein L (2002). Physiological significance of α(2)-adrenergic receptor subtype diversity: one receptor is not enough. Am J Physiol Regul Integr Comp Physiol 283 : R287 R295.
133. Piper BJ, Fraiman JB, Owens CB, Ali SF, Meyer JS (2008). Dissociation of the neurochemical and behavioral toxicology of MDMA ('ecstasy') by citalopram. Neuropsychopharmacology 33 : 1192 1205.
134. Qvigstad E, Sjaastad I, Bøkenes J, Schiander I, Solberg L, Sejersted OM et al 2005). Carvedilol blockade of α1- and β-adrenoceptor induced inotropic responses in rats with congestive heart failure. Eur J Pharmacol 516 : 51 59.
135. Rajamani K, Leong S, Lavelle A, Docherty JR (2001). Prejunctional actions of methylenedioxymethamphetamine in vas deferens from wild-type and α(2A/D)-adrenoceptor knockout mice. Eur J Pharmacol 423 : 223 228.
136. Reid WD, Volicer L, Smookler H, Beaven MA, Brodie BB (1968). Brain amines and temperature regulation. Pharmacology 1 : 329 344.
137. Rodsiri R, Marsden CA, Fone KCF, Green AR (2008). Changes in activity and temperature fail to correlate with 5-HT release following repeated MDMA administration in rats. J Psychopharmacol 22 : A65.
138. Romanovsky AA, Ivanov AI, Shimansky YP (2002). Ambient temperature for experiments in rats: a new method for determining the zone of thermal neutrality. J Appl Physiol 92 : 2667 2679.
139. Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI et al 2001). Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39 : 32 41.
140. Roti Roti JL (2008). Cellular responses to hyperthermia (40-46 degrees C): cell killing and molecular events. Int J Hyperthermia 24 : 3 15.
141. Rusyniak DE, Ootsuka Y, Blessing WW (2008). When administered to rats in a cold environment, 3,4-methylenedioxymethamphetamine reduces brown adipose tissue thermogenesis and increases tail blood flow: effects of pretreatment with 5-HT1A and dopamine D2 antagonists. Neuroscience 154 : 1619 1626.
142. Saadat KS, Elliott JM, Colado MI, Green AR (2004). Hyperthermic and neurotoxic effect of 3,4-methylenedioxymethamphetamine (MDMA) in guinea pigs. Psychopharmacology 173 : 452 453.
143. Saadat KS, O'Shea E, Colado MI, Elliott JM, Green AR (2005). The role of 5-HT in the impairment of thermoregulation observed in rats administered MDMA ('ecstasy') when housed at high ambient temperature. Psychopharmacology 179 : 884 890.
144. Sallinen J, Link RE, Haapalinna A, Viitamaa T, Kulatunga M, Sjöholm B et al 1997). Genetic alteration of α2C-adrenoceptor expression in mice: influence on locomotor, hypothermic, and neurochemical effects of dexmedetomidine, a subtype-nonselective α2-adrenoceptor agonist. Mol Pharmacol 51 : 36 46.
145. Sanchez V, Camarero J, O'Shea E, Green AR, Colado MI (2003). Differential effect of dietary selenium on the long-term neurotoxicity induced by MDMA in mice and rats. Neuropharmacology 44 : 449 461.
146. Sanchez V, O'Shea E, Saadat KS, Elliott JM, Colado MI, Green AR (2004). Effect of repeated ('binge') dosing of MDMA to rats housed at normal and high temperature on neurotoxic damage to cerebral 5-HT and dopamine neurones. J Psychopharmacol 18 : 412 416.
147. Schmidt CJ (1987). Acute administration of methylenedioxymethamphetamine: comparison with the neurochemical effects of its N-desmethyl and N-ethyl analogs. Eur J Pharmacol 136 : 81 88.
148. Schmidt CJ, Black CK, Abbate GM, Taylor VL (1990). Methylenedioxymethamphetamine-induced hyperthermia and neurotoxicity are independently mediated by 5-HT2 receptors. Brain Res 529 : 85 90.
149. Selvaraj S, Hoshi R, Bhagwagar Z, Murthy NV, Hinz R, Cowen P et al 2009). Brain serotonin transporter binding in former users of MDMA ('ecstasy'). Br J Psychiatry 194 : 355 359.
150. Shankaran M, Gudelsky GA (1999). A neurotoxic regime of MDMA suppresses behavioral, thermal and neurochemical responses to subsequent MDMA administration. Psychopharmacology 147 : 66 72.
151. Sharma HS, Hoopes PJ (2003). Hyperthermia induced pathophysiology of the central nervous system. Int J Hyperthermia 19 : 325 354.
152. Shioda K, Nisijima K, Yoshino T, Kuboshima K, Iwamura T, Yui K et al 2008). Risperidone attenuates and reverses hyperthermia induced by 3,4-methylenedioxymethamphetamine (MDMA) in rats. Neurotoxicology 29 : 1030 1036.
153. Sitte HH, Hiptmair B, Zwach J, Pifl C, Singer EA, Scholze P (2001). Quantitative analysis of inward and outward transport rates in cells stably expressing the cloned human serotonin transporter: inconsistencies with the hypothesis of facilitated exchange diffusion. Mol Pharmacol 59 : 1129 1137.
154. Sprague JE, Banks ML, Cook VJ, Mills EM (2003). Hypothalamic-pituitary- thyroid axis and sympathetic nervous system involvement in hyperthermia induced by 3,4-methylenedioxymethamphatamine (ecstasy). J Pharmacol Exp Ther 305 : 159 166.
155. Sprague JE, Brutcher RE, Mills EM, Caden D, Rusyniak DE (2004). Attenuation of 3,4-methylenedioxymethamphatamine (MDMA, ecstasy)-induced rhabdomyolysis with α1- plus β3-adrenoceptor antagonists. Br J Pharmacol 142 : 667 670.
156. Sprague JE, Moza P, Caden D, Rusyniak DE, Homes C, Goldstein DS et al 2005). Carvedilol reverses hyperthermia and attenuates rhabdomyolysis induced by 3,4-methylenedioxymethamphatamine (MDMA, ecstasy) in an animal model. Crit Care Med 33 : 1311 1316.
157. Srámek P, Simecková M, Janský L, Savlíková J, Vybíral S (2000). Human physiological responses to immersion into water of different temperatures. Eur J Appl Physiol 81 : 436 442.
158. Stuerenburg HJ, Petersen K, Bäumer T, Rosenkranz M, Buhmann C, Thomasius R (2002). Plasma concentrations of 5-HT, 5-HIAA, norepinephrine, epinephrine and dopamine in ecstasy users. Neuro Endocrinol Letts 23 : 259 261.
159. Taffe MA, Lay CC, Von Huben SN, Davis SA, Crean RD, Katner SN (2006). Hyperthermia induced by 3,4-methylenedioxymethamphetamine in unrestrained rhesus monkeys. Drug Alcohol Depend 82 : 276 281.
160. Tehan B (1993). Ecstasy and dantrolene. Br Med J 306 : 146.
161. Topp L, Hando J, Dillon P, Roche A, Solowij N (1999). Ecstasy use in Australia: patterns of use and associated harm. Drug Alcohol Depend 55 : 105 115.
162. de la Torre R, Farré M, Ortuño J, Mas M, Brenneisen R, Roset PN et al 2000). Non-linear pharmacokinetics of MDMA ('ecstasy') in humans. Br J Clin Pharmacol 49 : 104 109.
163. de la Torre R, Puerta E, Aguirre N (2009). Comment on the letter by Green, Gabrielsson, Marsden, Fone, MDMA: on the translation from rodent to human dosing. Psychopharmacology 204 : 379 380.
164. Tucker GT, Lennard MS, Ellis SW, Woods HF, Cho AK, Lin LY et al 1994). The demethylenation of methylenedioxymethamphetamine ('ecstasy') by debrisoquine hydroxylase (CYP2D6). Biochem Pharmacol 47 : 1151 1156.
165. Verma A, Kulkarni K (1993). Differential role of dopamine receptor subtypes in thermoregulation and stereotypic behavior in naïve and reserpinized rats. Arch Int Pharmacodyn Ther 324 : 17 32.
166. Vollenweider FX, Gamma A, Liechti M, Huber T (1998). Psychological and cardiovascular effects and short-term sequelae of MDMA ('ecstasy') in MDMA-naïve healthy volunteers. Neuropsychopharmacology 19 : 241 251.
167. Von Huben SN, Lay CC, Crean RD, Davis SA, Katner SN, Taffe MA (2007). Impact of ambient temperature on hyperthermia induced by (+/-)3,4- methylenedioxymethamphetamine in rhesus macaques. Neuropsychopharmacology 32 : 673 681.
168. Vrydag W, Michel MC (2007). Tools to study beta3-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol 374 : 385 398.
169. Winstock AR, Griffiths P, Stewart D (2001). Drugs and the dance music scene: a survey of current drug use patterns among a sample of dance music enthusiasts in the UK. Drug Alcohol Depend 64 : 9 17.
170. Yang JS, Jamei M, Heydari A, Yeo KR, de la Torre R, Farre M et al 2006). Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA. J Psychopharmacol 20 : 842 849.
171. Yehuda S, Wurtman RJ (1972a). Effects of d-amphetamine and related drugs on colonic temperatures of rats kept at various ambient temperatures. Life Sci 11 : 851 859.
172. Yehuda S, Wurtman RJ (1972b). Release of brain dopamine as probable mechanism for hypothermic effect of d-amphetamine. Nature 240 : 477 478.
173. Zarrindast MR, Sadeghi S, Sahebgharani M (2003). Influence of α-adrenoceptor agonists and antagonists on imipramine-induced hypothermia in mice. Pharmacol Toxicol 93 : 48 53.